Objective: To explore the efficacy and safety of methylprednisolone combined with dupilumab in the treatment of bullous pemphigoid(BP). Methods: 106 patients with BP admitted to department of dermatology were selected and divided into the conventional group and the dupilumab group based on their treatment regimens. Propensity score was used to match 53 patients in each group. The conventional group received intravenous methylprednisolone treatment, the dupilumab group received methylprednisolone (administered identically to the conventional group) combined with dupilumab treatment. Both groups were evaluated for efficacy at the 16 weeks treatment time point. The clinical efficacy, complete regression time of skin lesion, pruritus symptoms[pruritus number rating scale(NRS)score], skin lesion severity[BP disease area index(BPDAI)], serum anti-BP180 antibody, anti-BP230 antibody level, peripheral blood eosinophil (EOS) absolute value before and after treatment were compared between the two groups. The recurrence and adverse reactions of the two groups were counted after 6 months of follow-up. Results: The overall response rate in the dupilumab group was higher than that in the conventional group (P<0.05), the complete regression time of skin lesion was shorter than that in the conventional group (P <0.05). After treatment, the dupilumab group exhibited lower NRS scores, BPDAI scores, serum anti-BP180 antibody levels, anti-BP230 antibody levels, and absolute peripheral blood eosinophil count compared to the conventional group(P<0.05). At 6 months of follow-up, the recurrence rate in the dupilumab group with 11.32% was lower than 30.19% in the conventional group (P<0.05). There were no statistical differences in the incidence rates of adverse reactions between the dupilumab group and the conventional group (P >0.05). Conclusion: Methylprednisolone combined with dupilumab has significant efficacy in the treatment of BP, and it can effectively alleviate the severity of skin lesion, shorten the complete regression time of skin lesion, reduce the levels of autoantibodies and EOS and lower the risk of recurrence, with good safety.